BAFF receptor antibody for mantle cell lymphoma therapy

Mantle cell lymphoma (MCL) is an aggressive form of B cell non-Hodgkin’s lymphoma and remains incurable under current treatment modalities. One of the main reasons for treatment failure is the development of drug resistance. Accumulating evidence suggests that B cell activating factor (BAFF) and BAF...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Keman, Roy, Nand K, Vicioso, Yorleny, Woo, Janghee, Beck, Rose, de Lima, Marcos, Caimi, Paolo, Feinberg, Daniel, Parameswaran, Reshmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939563/
https://www.ncbi.nlm.nih.gov/pubmed/33747637
http://dx.doi.org/10.1080/2162402X.2021.1893501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939563/
https://www.ncbi.nlm.nih.gov/pubmed/33747637
http://dx.doi.org/10.1080/2162402X.2021.1893501

Ejemplares similares